2011
DOI: 10.2174/138920111798377120
|View full text |Cite
|
Sign up to set email alerts
|

Stem Cells in Pharmaceutical Biotechnology

Abstract: Multiple populations of stem cells have been indicated to potentially participate in regeneration of injured organs. Especially, embryonic stem cells (ESC) and recently inducible pluripotent stem cells (iPS) receive a marked attention from scientists and clinicians for regenerative medicine because of their high proliferative and differentiation capacities. Despite that ESC and iPS cells are expected to give rise into multiple regenerative applications when their side effects are overcame during appropriate pr… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
7
0
1

Year Published

2012
2012
2024
2024

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 7 publications
(8 citation statements)
references
References 130 publications
(208 reference statements)
0
7
0
1
Order By: Relevance
“…Pluripotent stem cells (PSC) are a promising source for production of different cell types for applications not only in cell‐based therapies but also in drug screening and toxicity testing . In addition to embryonic stem cells (ESC), initially generated from mice and later from humans, human induced pluripotent stem cells (hiPSC) have been introduced as a promising alternative to ESC .…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…Pluripotent stem cells (PSC) are a promising source for production of different cell types for applications not only in cell‐based therapies but also in drug screening and toxicity testing . In addition to embryonic stem cells (ESC), initially generated from mice and later from humans, human induced pluripotent stem cells (hiPSC) have been introduced as a promising alternative to ESC .…”
Section: Introductionmentioning
confidence: 99%
“…Pluripotent stem cells (PSC) are a promising source for production of different cell types for applications not only in cell-based therapies but also in drug screening and toxicity testing. 1 In addition to embryonic stem cells (ESC), initially generated from mice 2,3 and later from humans, 4 human induced pluripotent stem cells (hiPSC) have been introduced as a promising alternative to ESC. 5,6 In order to provide adequate cell numbers at a well defined quality for in vitro or in vivo applications a scale-up of PSC-production under good manufacturing practice (GMP) conditions is necessary.…”
Section: Introductionmentioning
confidence: 99%
“…Recently, the clinical application of stem cells, as therapeutic agents in ageing and ARDs, is acquiring a very consideration from the entire scientific community [ 44 , 45 ]. Stem cell therapy might, therefore, constitute a very solution for both delaying/retarding ageing processes and the onset/progression of ARDs and permitting to expand the survival of individuals.…”
Section: Stem Cells As Therapeutic Agents For Ageing and Ards?mentioning
confidence: 99%
“…The ability of human embryonic stem cells (hESC) to differentiate into various types of cells opened up a new era of in vitro toxicity testing 1 , disease modelling and regenerative medicine 2 . The stem cells are endowed with the capacity to self-replicate, to keep their pluripotent state, and to differentiate into specialized cells 3,4 .…”
Section: Introductionmentioning
confidence: 99%